IL234183A - The history of pyrazolotriazine as selective kinase antagonists with cyclin dependence - Google Patents
The history of pyrazolotriazine as selective kinase antagonists with cyclin dependenceInfo
- Publication number
- IL234183A IL234183A IL234183A IL23418314A IL234183A IL 234183 A IL234183 A IL 234183A IL 234183 A IL234183 A IL 234183A IL 23418314 A IL23418314 A IL 23418314A IL 234183 A IL234183 A IL 234183A
- Authority
- IL
- Israel
- Prior art keywords
- kinase inhibitors
- dependent kinase
- selective cyclin
- pyrazolotriazine
- derivatives
- Prior art date
Links
- PEYVWBGHBCDXRT-UHFFFAOYSA-N N1=NNC2=CN=NC2=C1 Chemical class N1=NNC2=CN=NC2=C1 PEYVWBGHBCDXRT-UHFFFAOYSA-N 0.000 title 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157751.4A EP2634190A1 (en) | 2012-03-01 | 2012-03-01 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| PCT/EP2013/054224 WO2013128028A1 (en) | 2012-03-01 | 2013-03-01 | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL234183A true IL234183A (en) | 2016-11-30 |
Family
ID=47757629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL234183A IL234183A (en) | 2012-03-01 | 2014-08-19 | The history of pyrazolotriazine as selective kinase antagonists with cyclin dependence |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9567345B2 (enExample) |
| EP (2) | EP2634190A1 (enExample) |
| JP (1) | JP6182549B2 (enExample) |
| KR (1) | KR101821452B1 (enExample) |
| CN (1) | CN104350054B (enExample) |
| AU (1) | AU2013224848B2 (enExample) |
| BR (1) | BR112014021189B1 (enExample) |
| CA (1) | CA2865946C (enExample) |
| DK (1) | DK2820020T3 (enExample) |
| ES (1) | ES2583231T3 (enExample) |
| HU (1) | HUE029264T2 (enExample) |
| IL (1) | IL234183A (enExample) |
| MX (1) | MX347359B (enExample) |
| RU (1) | RU2645347C2 (enExample) |
| SG (1) | SG11201405129RA (enExample) |
| WO (1) | WO2013128028A1 (enExample) |
| ZA (1) | ZA201406078B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| EP3129371B1 (en) * | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2966164C (en) | 2014-10-31 | 2023-10-17 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
| ES2899196T3 (es) * | 2015-03-09 | 2022-03-10 | Aurigene Discovery Tech Ltd | Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK |
| MX394157B (es) | 2015-06-15 | 2025-03-24 | Ube Corp | Derivado de dihidropirrolopirazol sustituido. |
| AU2016284638B2 (en) * | 2015-06-24 | 2020-01-23 | Curovir Ab | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| CN106432249B (zh) * | 2016-09-30 | 2018-12-04 | 陕西科技大学 | 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途 |
| EP3664806B1 (en) | 2017-08-09 | 2025-04-30 | Sanford Burnham Prebys Medical Discovery Institute | 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| CA3088347A1 (en) * | 2018-01-17 | 2019-07-25 | Glaxosmithkline Intellectual Property Development Limited | Pi4kiii.beta. inhibitors |
| US12606561B2 (en) | 2018-04-11 | 2026-04-21 | Qurient Co., Ltd. | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors |
| KR20200141487A (ko) * | 2018-04-11 | 2020-12-18 | 주식회사 큐리언트 | 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체 |
| BR112020020645A2 (pt) * | 2018-04-11 | 2021-01-12 | Qurient Co., Ltd. | Derivados farmaceuticamente aceitáveis de pirazol-triazina e/ou pirazol-pirimidina |
| US11517568B2 (en) | 2018-09-12 | 2022-12-06 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| US11364234B2 (en) | 2018-09-12 | 2022-06-21 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| CR20210287A (es) | 2018-11-01 | 2022-02-15 | Syros Pharmaceuticals Inc | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) |
| EP3885347B1 (en) | 2018-11-14 | 2023-11-22 | UBE Corporation | Dihydropyrrolopyrazole derivative |
| CN110101703B (zh) * | 2019-05-06 | 2021-06-11 | 暨南大学 | Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用 |
| RU2713152C1 (ru) * | 2019-08-30 | 2020-02-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения хронической аллергической крапивницы на фоне описторхоза |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| CN116964061A (zh) * | 2020-12-21 | 2023-10-27 | 詹森药业有限公司 | 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环嘧啶 |
| US20250281495A1 (en) * | 2021-02-25 | 2025-09-11 | Icahn School Of Medicine At Mount Sinai | Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease |
| CN116940577A (zh) * | 2021-03-09 | 2023-10-24 | 詹森药业有限公司 | 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环吡啶 |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| EP4377312A1 (en) | 2021-07-29 | 2024-06-05 | Syngenta Crop Protection AG | Pesticidally active fused bicyclic heteroaromatic compounds |
| US20250019382A1 (en) * | 2021-11-23 | 2025-01-16 | Origenis Gmbh | Novel inhibitors of cyclin-dependent kinases |
| CN114181217B (zh) * | 2022-01-10 | 2022-12-27 | 陕西师范大学 | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
| EP4493193A1 (en) * | 2022-03-18 | 2025-01-22 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| HK1044334A1 (zh) * | 1999-02-01 | 2002-10-18 | Cv治疗公司 | 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂 |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AR047969A1 (es) * | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| FR2943058B1 (fr) * | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| CZ302711B6 (cs) * | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
-
2012
- 2012-03-01 EP EP12157751.4A patent/EP2634190A1/en not_active Withdrawn
-
2013
- 2013-03-01 CN CN201380011917.5A patent/CN104350054B/zh active Active
- 2013-03-01 BR BR112014021189-2A patent/BR112014021189B1/pt active IP Right Grant
- 2013-03-01 AU AU2013224848A patent/AU2013224848B2/en active Active
- 2013-03-01 DK DK13707008.2T patent/DK2820020T3/en active
- 2013-03-01 JP JP2014559259A patent/JP6182549B2/ja active Active
- 2013-03-01 US US14/381,146 patent/US9567345B2/en active Active
- 2013-03-01 KR KR1020147027812A patent/KR101821452B1/ko active Active
- 2013-03-01 HU HUE13707008A patent/HUE029264T2/en unknown
- 2013-03-01 WO PCT/EP2013/054224 patent/WO2013128028A1/en not_active Ceased
- 2013-03-01 CA CA2865946A patent/CA2865946C/en active Active
- 2013-03-01 SG SG11201405129RA patent/SG11201405129RA/en unknown
- 2013-03-01 ES ES13707008.2T patent/ES2583231T3/es active Active
- 2013-03-01 EP EP13707008.2A patent/EP2820020B1/en active Active
- 2013-03-01 MX MX2014010494A patent/MX347359B/es active IP Right Grant
- 2013-03-01 RU RU2014139705A patent/RU2645347C2/ru active
-
2014
- 2014-08-19 IL IL234183A patent/IL234183A/en active IP Right Grant
- 2014-08-19 ZA ZA2014/06078A patent/ZA201406078B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865946C (en) | 2020-01-21 |
| HUE029264T2 (en) | 2017-02-28 |
| CN104350054A (zh) | 2015-02-11 |
| ZA201406078B (en) | 2016-08-31 |
| EP2820020A1 (en) | 2015-01-07 |
| US20150018329A1 (en) | 2015-01-15 |
| MX2014010494A (es) | 2015-04-08 |
| EP2820020B1 (en) | 2016-04-06 |
| KR101821452B1 (ko) | 2018-01-23 |
| SG11201405129RA (en) | 2014-09-26 |
| CN104350054B (zh) | 2017-06-13 |
| EP2634190A1 (en) | 2013-09-04 |
| JP6182549B2 (ja) | 2017-08-16 |
| CA2865946A1 (en) | 2013-09-06 |
| BR112014021189B1 (pt) | 2022-08-16 |
| KR20140131994A (ko) | 2014-11-14 |
| DK2820020T3 (en) | 2016-07-04 |
| RU2014139705A (ru) | 2016-04-20 |
| WO2013128028A8 (en) | 2014-10-02 |
| MX347359B (es) | 2017-04-06 |
| AU2013224848B2 (en) | 2017-06-29 |
| BR112014021189A2 (enExample) | 2017-06-20 |
| ES2583231T3 (es) | 2016-09-19 |
| JP2015511952A (ja) | 2015-04-23 |
| AU2013224848A1 (en) | 2014-08-28 |
| US9567345B2 (en) | 2017-02-14 |
| HK1206014A1 (en) | 2015-12-31 |
| WO2013128028A1 (en) | 2013-09-06 |
| RU2645347C2 (ru) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234183A (en) | The history of pyrazolotriazine as selective kinase antagonists with cyclin dependence | |
| IL261282A (en) | Furinone compounds as kinase inhibitors | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| IL238728A0 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| ZA201501615B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
| IL239193A0 (en) | New Benzimidazole Derivatives as Kinase Inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| IL237475A0 (en) | Pyrlotriazinone derivatives as pi3k inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| EP2903970A4 (en) | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | |
| PL2912041T3 (pl) | Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| AP2016009293A0 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| ZA201508968B (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| EP2900243A4 (en) | BICYCLIC OXA LACTAM KINASE HEMMER | |
| IL235935A0 (en) | Transmutable kinase inhibitor picolinamides | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |